Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.44 |
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | DRD4 | P21917 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6978349 | 0.84 | GFER (0.55) | DRD3DRD2DRD4ALDH1A1AKR1C3 | |
| SCHEMBL6978355 | 0.84 | GFER (0.55) | DRD3DRD2DRD4ALDH1A1AKR1C3 | |
| SCHEMBL6978386 | 0.79 | KMT2A (0.49) | DRD3DRD2DRD4ALDH1A1RAB9A | |
| SCHEMBL6978390 | 0.79 | KMT2A (0.49) | DRD3DRD2DRD4ALDH1A1RAB9A | |
| SCHEMBL6981803 | 0.73 | ADAM10 (0.40) | DRD3DRD2DRD4ALDH1A1AKR1C3 | |
| SCHEMBL6979020 | 0.72 | SMN1; SMN2 (0.49) | DRD3DRD2DRD4NPC1ALDH1A1 | |
| SCHEMBL6979028 | 0.72 | SMN1; SMN2 (0.49) | DRD3DRD2DRD4NPC1ALDH1A1 | |
| SCHEMBL27484010 | 0.71 | GFER (0.50) | ALDH1A1NPSR1HTR7GFERMAPT | |
| SCHEMBL6981151 | 0.70 | TGM2 (0.45) | DRD3DRD2DRD4ALDH1A1AKR1C3 | |
| SCHEMBL6978563 | 0.70 | CCR1 (0.50) | ALDH1A1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0838460-A1 | PIPERAZINE DERIVATIVES AND USE OF THE SAME | Senju Pharmaceutical Co., Ltd. (JP) | 1998-04-29 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |